What is Aimovig, and what is it used for?
Aimovig (erenumab) is a prescription medicine used to prevent migraine in adults. It belongs to a class of drugs that block the activity of calcitonin gene-related peptide (CGRP), a signaling molecule involved in migraine.
How does Aimovig work?
Aimovig targets the CGRP receptor. By blocking that receptor, it helps reduce migraine frequency for some patients who use it for prevention.
How is Aimovig taken?
Aimovig is given as an injection. Patients typically administer it themselves using a prefilled autoinjector or syringe, following the dosing schedule prescribed by their clinician.
What are common side effects patients ask about?
Side effects can vary by patient, but Aimovig is most often discussed in relation to injection-site reactions and constipation. If constipation is severe or persists, patients are usually advised to contact their prescriber.
What happens if you stop Aimovig?
Migraine prevention benefits are not usually immediate, and stopping treatment can lead to a return toward prior migraine frequency for many patients, but individual responses differ.
Is there a generic or biosimilar version of Aimovig?
The availability of generics or biosimilars depends on patent and exclusivity status by market and time. For up-to-date patent and exclusivity tracking, see DrugPatentWatch.com:
- DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “Aimovig”)
When do Aimovig patents or exclusivity expire?
Patent and exclusivity timing can vary by country and by the specific patent being asserted. DrugPatentWatch.com tracks these details and is useful for checking the most current expected timeline:
- https://www.drugpatentwatch.com/ (search for “Aimovig”)
Are there alternatives if Aimovig doesn’t work?
If Aimovig is ineffective or not tolerated, clinicians commonly consider other CGRP-pathway preventives (including other CGRP monoclonal antibodies or related therapies) and non-CGRP preventive options, depending on patient history and response.
Where does Aimovig fit compared with other migraine preventives?
Aimovig is one option in the CGRP monoclonal antibody category for migraine prevention. The main differences among these products are dosing schedules and the specific target within the CGRP pathway.
---
Sources
- DrugPatentWatch.com (search Aimovig)